Glaxo Keeps Alli As Recently Pruned Consumer Division Thrives

GlaxoSmithKline abandons its attempt to divest the OTC weight loss aid alli, even though the beleaguered brand continues to drag down consumer division sales. The division’s sales climbed 7% excluding alli in the firm’s second quarter, but only 5% including the product’s results.

GlaxoSmithKline Inc. abandoned its attempt to sell the alli brand and recommitted to promoting the beleaguered OTC weight loss aid, although it continues to drag down consumer health care product sales.

More from United States

More from North America